Wedbush Comments on Vor Biopharma’s Q3 Earnings (NYSE:VOR)

Vor Biopharma Inc. (NYSE:VOR) – Stock analysts at Wedbush increased their Q3 2025 earnings estimates for Vor Biopharma in a research note issued to investors on Wednesday, August 13th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($0.03) per share for the quarter, up from their prior estimate of ($0.19). Wedbush has a “Outperform” rating on the stock. The consensus estimate for Vor Biopharma’s current full-year earnings is ($1.42) per share. Wedbush also issued estimates for Vor Biopharma’s Q4 2025 earnings at ($0.03) EPS, Q1 2026 earnings at ($0.03) EPS, Q2 2026 earnings at ($0.03) EPS, Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at ($0.03) EPS and FY2026 earnings at ($0.14) EPS.

A number of other research firms have also weighed in on VOR. Baird R W lowered shares of Vor Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 8th. Jones Trading lowered shares of Vor Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 8th. Citizens Jmp lowered shares of Vor Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 9th. JMP Securities reaffirmed a “market perform” rating and set a $6.00 price target on shares of Vor Biopharma in a research report on Friday, May 9th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target on shares of Vor Biopharma in a research report on Thursday. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $6.07.

Vor Biopharma Trading Up 8.1%

Shares of VOR opened at $2.14 on Friday. The stock has a market cap of $271.01 million, a P/E ratio of -1.30 and a beta of 2.06. The company has a 50-day moving average of $1.59 and a two-hundred day moving average of $1.04. Vor Biopharma has a 12-month low of $0.13 and a 12-month high of $3.29.

Institutional Investors Weigh In On Vor Biopharma

Several institutional investors have recently bought and sold shares of VOR. RA Capital Management L.P. grew its stake in Vor Biopharma by 74.3% during the fourth quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company’s stock worth $44,007,000 after buying an additional 16,897,159 shares during the period. Lynx1 Capital Management LP purchased a new stake in Vor Biopharma during the fourth quarter worth approximately $707,000. Jane Street Group LLC purchased a new stake in Vor Biopharma during the first quarter worth approximately $140,000. OMERS ADMINISTRATION Corp purchased a new stake in Vor Biopharma during the first quarter worth approximately $100,000. Finally, Trustees of Columbia University in the City of New York purchased a new stake in Vor Biopharma during the fourth quarter worth approximately $102,000. 97.29% of the stock is currently owned by hedge funds and other institutional investors.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.